Efficacy of photobiomodulation therapy combined with mobile health education in patients with head and neck cancer suffering from chronic xerostomia after radiotherapy: protocol for a three-arm, randomised, placebo-controlled, double-blinded study
Lopez-Garzon,M.,Lopez-Fernandez,M. D.,Ruiz-Martinez,A. M.,Galvan-Banqueri,P.,Lozano-Lozano,M.,Tovar-Martin,I.,Postigo-Martin,P.,Ariza-Vega,P.,Artacho-Cordon,F.,Fernandez-Lao,C.,Cantarero-Villanueva,I.,Fernandez-Gualda,M. A.,Arroyo-Morales,M.,Ruiz-Villaverde,R.,Galiano-Castillo,N.
DOI: https://doi.org/10.1136/bmjopen-2023-078068
IF: 3.006
2024-01-25
BMJ Open
Abstract:Introduction The role of photobiomodulation (PBM) therapy for oral tissue damage induced by cancer treatment is currently unclear, and there is low-quality to moderate-quality evidence supporting the use of this approach for treating xerostomia and/or hyposalivation. Consequently, patients with head and neck cancer increasingly turn to basic oral hygiene to alleviate salivary gland dysfunction, and their adherence can be improved by mobile health (mHealth) education. The primary objective of this study will be to analyse the effects of different doses of PBM therapy (7.5 J/cm 2 vs 3 J/cm 2 ) plus mHealth education on quality of life (QoL), oral health, salivary secretion and salivary gland ultrasound assessment at postintervention and at the 6-month follow-up in patients with head and neck cancer after radiotherapy compared with those in control group. Methods and analysis A prospective, three-arm, randomised, placebo-controlled, double-blinded study will be conducted among patients with head and neck cancer suffering from chronic xerostomia. A total of 20 patients per arm will be included and randomly assigned to receive 7.5 J/cm 2 of PBM, 3 J/cm 2 of PBM or placebo therapy. PBM therapy will be applied during 24 sessions at 22 points extra and intraorally two times per week for 3 months, combined with a mobile application (https://www.laxer.es). The assessments will be recorded at the beginning of the study, at postintervention and at the 6-month follow-up. The primary outcomes will be QoL, oral health, salivary secretion and salivary gland ultrasound. The pain pressure threshold, functional performance, mood and sleep quality will be secondary indicators. Ethics and dissemination This study received ethics approval from the Andalusian Biomedical Research Ethics Portal (2402-N-21 CEIM/CEI Provincial de Granada) according to the Declaration of Helsinki for Biomedical Research. The results of this study will be presented at national and international conferences and published in peer-reviewed journals. Trial registration number ClinicalTrials.gov NCT05106608.
medicine, general & internal